首页> 外文期刊>Journal of Allergy >TNF-Alpha Inhibitors for Chronic Urticaria: Experience in 20 Patients
【24h】

TNF-Alpha Inhibitors for Chronic Urticaria: Experience in 20 Patients

机译:TNF-α抑制剂治疗慢性荨麻疹:20例患者的经验

获取原文
           

摘要

Patients with severe chronic urticaria may not respond to antihistamines, and other systemic treatment options may either be ineffective or associated with unacceptable side effects. We present data on efficacy and safety of adalimumab and etanercept in 20 adult patients with chronic urticaria. Twelve (60%) patients obtained complete or almost complete resolution of urticaria after onset of therapy with either adalimumab or etanercept. Further three patients (15%) experienced partial response. Duration of treatment ranged between 2 and 39 months. Those responding completely or almost completely had a durable response with a mean of 11 months. Six patients (30%) experienced side effects and five patients had mild recurrent upper respiratory infections, whereas one patient experienced severe CNS toxicity that could be related to treatment with TNF-alpha inhibitor. Adalimumab and etanercept may be effective and relatively safe treatment options in a significant proportion of patients with chronic urticaria who do not respond sufficiently to high-dose antihistamines or in whom standard immunosuppressive drugs are ineffective or associated with unacceptable side effects.
机译:患有严重慢性荨麻疹的患者可能对抗组胺药无反应,其他全身性治疗选择可能无效或伴有不可接受的副作用。我们提供了20名成年慢性荨麻疹患者中阿达木单抗和依那西普的疗效和安全性数据。在开始使用阿达木单抗或依那西普治疗后,有十二名(60%)患者获得了完全或几乎完全的荨麻疹消退。另外三名患者(15%)经历了部分缓解。治疗持续时间在2到39个月之间。那些完全或几乎完全响应的人有一个平均11个月的持久响应。 6例患者(30%)出现副作用,5例患者出现轻度复发的上呼吸道感染,而1例患者出现严重的中枢神经系统毒性,这可能与TNF-α抑制剂治疗有关。阿达木单抗和依那西普在相当大比例的慢性荨麻疹患者中可能是有效且相对安全的治疗选择,这些患者对高剂量的抗组胺药没有足够的反应或标准免疫抑制药物无效或伴有不可接受的副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号